Yingke Capital is a principal investment firm founded in 2010 and headquartered in Fuzhou, China. The firm specializes in pre-IPO investments, focusing on sectors such as 5G internet of things, biomedical, environmental and facilities services, new energy, consumer upgrades, smart manufacturing, and materials. Yingke Capital typically invests in companies with strong technology R&D and production capabilities, participating in Series B, C, and D funding rounds.
Notable portfolio companies include Cloudbreak Therapeutics, Denovo Biopharma, Joinn Biologics, and Simcere Pharmaceutical, with significant total capital raised by each. The firm was founded by Mingfei Qian and emphasizes a high-tech investment philosophy. Yingke Capital offers unique value-add services to its portfolio companies, leveraging its deep industry expertise and extensive network to support growth and innovation.
Yingke Capital - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Portfolio Companies7
Current Portfolio Count7
Top Investment Stages
Series B3 (42.9%)
Series C2 (28.6%)
Series A1 (14.3%)
Series D1 (14.3%)
Stage Mix
Series B 43%Series C 29%Series A 14%Series D 14%
Concentration shown as share of disclosed investments by stage.
